Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: AgAuUSA who wrote (8221)	2/24/1998 8:19:00 PM
From: Keiko	Read Replies (1) \| Respond to of 14328

Greg, About a year ago, you did some searching for patents and how they apply to the Unigold and Sero-card technology. It is my understanding , and correct me if I am wrong, didn't we inherit those HIV 1 and HIV 2 licenses over one year ago ? As you know Pastuer Sanofi ( Paris ) had the original licenses on HIV 1 & 2 .I have spoken to Trinity several times and they claim we have no problem with these patents as they apply to Sero-card and Uni-gold but we get a different version from the CDC. What are your thoughts on this subject ? Do these license agreements present any roadblocks ? Does it only apply to HIV-2 ? Quote from CDC Alert.... " For one thing, Paris - based Sanofi Diagnostics, Pastuer, holds patent rights in the United States to the HIV-2 antigen, which the FDA says new HIV tests must be able to detect to be approved. Thus, it's possible other companies submitting products for licensure could face a court challenge." Hopefully, someone from Dublin will comment on these license agreements very soon.